Navigation Links
Shire Completes Acquisition of Advanced BioHealing, Inc.
Date:6/28/2011

DUBLIN, June 28, 2011 /PRNewswire/ --


 

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the satisfaction of the closing conditions, including the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the acquisition of Advanced BioHealing, Inc. ("ABH"), as first announced on May 17, 2011, has been completed.

The Advanced BioHealing business becomes part of Shire's Specialty Pharmaceuticals business, led by Mike Cola, and will leverage biologic manufacturing expertise from Shire's Human Genetic Therapies business. Kevin Rakin, Chief Executive Officer of Advanced BioHealing, will continue to lead this business within the Shire organization.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.


"SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Investor Relations Eric Rojas (erojas@shire.com) +1-781-482-0999 Sarah Elton-Farr (seltonfarr@shire.com) +44(0)1256-894157 Media Jessica Mann (jmann@shire.com) +44(0)1256-894-280 Matthew Cabrey (mcabrey@shire.com) +1-484-595-8248


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/19/2017)... 19, 2017 Cardiology devices segment is anticipated to ... The Cardiology Devices segment is likely to create absolute ... in 2018 over 2017. By the end of 2027, Cardiology ... to US$ 700 Mn, expanding at a CAGR of 18.4% ... Asia Pacific reprocessed medical devices market ...
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... are expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) ... greater use of this type of healthcare model in the diagnosis and treatment ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... As ... is worth a thousand words. The good news for single women is that she ... Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling sense ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... Gallardo, DDS, PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium ... , The Oral Reconstruction Foundation will present its annual Global Symposium at the ...
(Date:4/24/2017)... ... 24, 2017 , ... A 2-in-1 bottleless water appliance provides ... 101 Water Texas, here are the ways in which this technology can benefit ... of pure, fresh, oxygenated water, with both cold and hot options. , Convenience ...
Breaking Medicine News(10 mins):